logo-loader

Avacta Group PLC

Receive alerts
Market:
AIM
Market Cap:
£33.26 m
Price
18.90 GBX
Change
-1.81%
52 weeks high
49.80
52 weeks low
15.00

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.

Deep dive We explore the investor case for growth companies

Snapshot

Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences